Encapsulation of the Antistaphylococcal Endolysin LysRODI in pH-Sensitive Liposomes
Open Access
- 8 May 2020
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 9 (5), 242
- https://doi.org/10.3390/antibiotics9050242
Abstract
Phage lysins are promising new therapeutics against multidrug-resistant bacteria. These so-called enzybiotics offer, amongst their most notable advantages, high target specificity and low resistance development. Moreover, there are numerous recent and ongoing studies aimed at demonstrating the efficacy and safety of endolysins in animal models or even in clinical trials. Nonetheless, as is the case for other antimicrobials, it is important to assess potential strategies that may broaden their potential applications or improve their stability. Encapsulation, for instance, has given very good results for some antibiotics. This study sought to evaluate the feasibility of encapsulating an endolysin against the opportunistic human pathogen Staphylococcus aureus, one of the most problematic bacteria in the context of the current antibiotic resistance crisis. Endolysin LysRODI has antimicrobial activity against many S. aureus strains from different sources, including methicillin-resistant S. aureus (MRSA) isolates. Here, this protein was encapsulated in pH-sensitive liposomes with an efficacy of approximately 47%, retaining its activity after being released from the nanocapsules. Additionally, the encapsulated endolysin effectively reduced S. aureus cell counts by > 2log units in both planktonic cultures and biofilms upon incubation at pH 5. These results demonstrate the viability of LysRODI encapsulation in liposomes for its targeted delivery under mild acidic conditions.Funding Information
- CSIC (CSIC201670E040 & CSIC 201770E016)
- CONACyT (Postdoctoral fellowship)
This publication has 23 references indexed in Scilit:
- Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus ?mBio, 2018
- Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial)Trials, 2017
- Successful Treatment of Chronic Staphylococcus aureus-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 CasesCase Reports in Dermatology, 2017
- Thermally triggered release of the bacteriophage endolysin CHAPK and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA)Journal of Controlled Release, 2017
- Epidemiology and microbiology of skin and soft tissue infectionsCurrent Opinion in Infectious Diseases, 2016
- Application of liposomes in medicine and drug deliveryArtificial Cells, Nanomedicine, and Biotechnology, 2014
- Enhanced Staphylolytic Activity of the Staphylococcus aureus Bacteriophage vB_SauS-phiIPLA88 HydH5 Virion-Associated Peptidoglycan Hydrolase: Fusions, Deletions, and Synergy with LysH5Applied and Environmental Microbiology, 2012
- Endolysins as AntimicrobialsPublished by Elsevier BV ,2012
- Bacteriophage lysins as effective antibacterialsCurrent Opinion in Microbiology, 2008
- Vancomycin-Modified Nanoparticles for Efficient Targeting and Preconcentration of Gram-Positive and Gram-Negative BacteriaACS Nano, 2008